Large Vessel Vasculitis
Conditions
Keywords
Large Vessel Vasculitis, PET, MRA, SUVmax, TBA
Brief summary
Large vessel vasculitis (LVV) causes vascular inflammation, leading to serious complications such as aneurysm formation and stroke. It is difficult to identify the inflammation of the vessel wall by the current imaging methods, thus affecting the timing of treatment and selection of treatment options. Improved examination methods to determine disease activity are highly needed to guide treatment.
Detailed description
This study was designed to assess vascular wall inflammation in patients with large vessel vasculitis by positron emission tomography and magnetic resonance imaging (PET/MRA). The study has a 12-month follow-up period. After completing the baseline clinical assessment, laboratory test and PET/MRA assessment, the intervention protocol will be determined by clinicians. The patients will visit the clinic every 1-2 months according to their specific conditions. Clinical assessment, laboratory test and PET/MRA re-examination will be completed at 6 and 12 months after treatment.
Interventions
DRUGglucocorticoid, immunosuppressants, targeted therapy
Drug intervention protocol will be determined by clinicians
Sponsors
Nanjing Medical University
Study design
Observational model
COHORT
Time perspective
RETROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
1. Clinically suspected or confirmed LVV and willing to undergo PET/MRA 2. Compliance with long-term follow-up 3. Sign informed consent.
Exclusion criteria
1. Patients with other serious cardiovascular and cerebrovascular diseases, malignant tumors, infectious diseases, severe renal insufficiency. 2. Severe mental disorders, severe claustrophobia unable to cooperate with the examination. 3. Patients equipped with cardiac pacemaker, artificial heart valve, ferromagnetic vascular clamp after vascular surgery, aneurysm clamp, artificial cochlea, insulin pump and other drug dosage control devices, steel nail plate and other metal internal fixation, artificial joint, electronic eye, artificial eye. 4. Allergic to contrast medium. 5. Pregnant or lactating women. Withdrawal criteria: 1. Any
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Vascular structural progression | 12 months | Vascular structural progression indicated by PET/MRA (including new vessel wall thickening, increased thickening, vascular stenosis or occlusion, aneurysm formation) |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| SUV max | 12 months | Standardized uptake values（SUV） is a semiquantitative measurement of tumor uptake of FDG derived by measuring the ratio of radioactivity in the tumor to the expected baseline activity in the body. The SUVmax is defined as the maximum value for SUV in a Volume of interest (VOI) representing the highest metabolism in the tumor. |
| TBA | 12 months | A template-based approach (TBA) consists in matching a model to the patient's anatomy so that the known attenuation map from the model can be applied to the patient data. |
Countries
China
Contacts
Primary ContactRui LIU, MD
Backup ContactQian ZHANG, MD
Outcome results
None listed